Tags |
|
|
Links |
|
|
Advice You - Medical Billing - DME Software Security
In this installment of medical billing and DME software, we're going to cover the topic of security, which can actually apply to any type of medical billing
According to USFDA, a combination product is one composed of any combination of a drug and device; biological product and device; drug and biological product
software since security is such a big issue these days.
The whole topic of security pretty much stems from the HIPAA privacy rules. These rules cover jus
The whole topic of security pretty much stems from the HIPAA privacy rules. These rules cover jus
; or drug, device, and biological product and fixed dose combination would include two or more combinations of drug.
Examples of combination products may in
Examples of combination products may in
t about everything, including health plans, health care providers, health care clearinghouses and billing agencies. If you're associated with the medical p
lude drug-coated devices, drugs packaged with delivery devices in medical kits, and drugs and devices packaged separately but intended to be used together.
rofession in any manner shape or form, you are probably under the HIPAA privacy rule umbrella.
The main information that is protected by the HIPAA privacy
The main information that is protected by the HIPAA privacy
here is enormous increase in the number of combination products entering the market in the recent years. Combination products have proven advantages but fixe
rule is the patient's past, present, or future medical condition, the provision of health care to the patient, the past, present or future health care to th
d dose combinations are still in the process of convincing regulatory authority on their advantages over the single ingredient formulations.
Combination pro
Combination pro
e patient and all the patient's private information including social security number, EIN, or any other private information of the patient, including paymen
ucts have become life saving products for the pharmaceutical companies who doesn’t have many innovative molecules in their product pipeline and have been inc
ts made by the patient or to the patient.
The above is extremely simplified, as the law is pages long. There are also some limited disclosures that are al
The above is extremely simplified, as the law is pages long. There are also some limited disclosures that are al
easingly used in the product life cycle management. Even the companies having product patents are trying to extend their product life cycle through the combi
lowed. Some covered agencies are allowed access to this information but they have to show just cause why they need it, such as police, prosecutors, etc. W
nation products and maximize the revenues. But the companies involved in this practice are overlooking that they are burdening the patients both economically
here this complicates things is with billers. While the billing agency itself needs to know this information in order to properly bill the patient and insu
and physically. They need to rightly judge the benefits of the combination products and they have to even look at the risks involved when combining the produ
rance company, there has been a lot of heated argument about who in the billing agency should have access to this information. Because of this, only people
ts. Some of the combination products were well accepted by physicians while others suffered. Companies involved in development of combination products are fi
directly involved with the actual billing are granted access to this information. Therefor, non billers, of which there are plenty in a billing house, are
ding difficulty in defining their combination products and facing various challenges from selecting a combination to marketing it.
Following aspects would a
Following aspects would a
not allowed access to this information. This is where the problem comes in.
The solution is DME software security. By restricting workers to certain par
The solution is DME software security. By restricting workers to certain par
dd to the challenges in developing combination products:
Which markets to tap where the combination products can do fairly well?
Which combination prod
Which markets to tap where the combination products can do fairly well?
Which combination prod
ts of the system, such as inventory personnel, the administrator of the software can make it so that these people are only given access to their area and th
cts are meaningful and rational?
Which therapeutic categories to select?
Which Combinations can address unmet needs of the patients?
Do combin
Which therapeutic categories to select?
Which Combinations can address unmet needs of the patients?
Do combin
erefor gain no access to patient records. This is done in the security options section of the software under each users name.
Most software will have basi
Most software will have basi
tions increase the patient compliance?
What would be the developing cost?
How to tackle the risks encountered during combination product developmen
What would be the developing cost?
How to tackle the risks encountered during combination product developmen
c access categories so that the administrator doesn't have to go into each individual section and give and deny access one section at a time. By having cat
t?
As combination products don't fit into the traditional categories of drugs, medical devices, or biological products, the USFDA is in the process of devel
As combination products don't fit into the traditional categories of drugs, medical devices, or biological products, the USFDA is in the process of devel
egories, such as biller, inventory, supervisor, etc., the administrator can just assign a category to the worker and the programs associated with that categ
ping new procedures for reviewing their safety, efficacy and quality.
Professional from academic institutions, pharmaceutical industries, health care indust
Professional from academic institutions, pharmaceutical industries, health care indust
ory are then given to the worker. All other programs are blocked. If individual program access is needed under special circumstances, this is also provide
y and representatives from various regulatory agencies are working out to design the regulatory requirements for manufacture and sale of combination products
d by the software as well.
The job of the software administrator is not an easy one. For one thing, most administrators themselves are not billers and the
The job of the software administrator is not an easy one. For one thing, most administrators themselves are not billers and the
.
As there is an increasing trend of the combination products companies manufacturing such products should be able to tackle the problems involved in the de
As there is an increasing trend of the combination products companies manufacturing such products should be able to tackle the problems involved in the de
refor are only allowed certain access. So while they are allowed to give access to patient records to various people, they themselves are not allowed this
elopment. They need to be wiser in analyzing the market trends and the regulatory requirements.
Companies that provide selfless information through particip
Companies that provide selfless information through particip
access. It's a tricky situation to have to deal with but not impossible if the security is set up just so. This makes medical billing just a little easier
tion in industry events and feedback to regulatory authorities would be able to face the challenges and will be successful in developing combination products
HTTP = HTML link (for blogs, profiles,phorums):
<a href="http://www.adviceyou.org.ua/article/2002/adviceyou-Medical-Billing--DME-Software-Security.html">Medical Billing - DME Software Security</a>
BB link (for phorums):
[url=http://www.adviceyou.org.ua/article/2002/adviceyou-Medical-Billing--DME-Software-Security.html]Medical Billing - DME Software Security[/url]
Related Articles:
Fully Customizable Registration Forms
Bookmark it:
|